Over-expression of MiR-98 in FFPE Tissues Might Serve As a Valuable Source for Biomarker Discovery in Breast Cancer Patients

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2014 Apr 4

PMID 24696733

Citations 18

Authors

Zhao-Qun Deng

Jia-Yu Yin

Qin Tang

Feng-Qiong Liu

Jun Qian

Jiang Lin

Rui Shao

Ming Zhang

Li He

Affiliations

Soon will be listed here.

Abstract

The miR-98 is thought to be associated with various cancers. This study was to evaluate the potential predictive value of miR-98 expression in formalin-fixed paraffin-embedded tissue of breast cancer patients. The expression levels of miR-98 were examined in 98 breast cancer patients and 40 cancer-free controls using real-time quantitative PCR. The comparison of miR-98 expression levels between patient and control was performed using the Mann-Whitney test. The miR-98 showed higher expression levels in breast cancer patients compared with cancer free controls (p<0.01). The expression levels of miR-98 were highly correlated with miR24/93/378 in breast cancer patients. The miR-98 exhibited great capability of discriminating between cancer patients and controls by the Receiver-operator characteristic (ROC) curve analysis. The miR-98 was found highly correlated with breast cancer by Univariable logistic regression analysis. These results suggest that over-expression of miR-98 in formalin-fixed paraffin-embedded tissues might serve as a valuable source for biomarker discovery in breast cancer patients.

Citing Articles

MicroRNA-98: the multifaceted regulator in human cancer progression and therapy.

Hazari V, Samali S, Izadpanahi P, Mollaei H, Sadri F, Rezaei Z Cancer Cell Int. 2024; 24(1):209.

PMID: 38872210 PMC: 11177407. DOI: 10.1186/s12935-024-03386-2.

Non-Coding RNA-Dependent Regulation of Mitochondrial Dynamics in Cancer Pathophysiology.

Gallo Cantafio M, Torcasio R, Viglietto G, Amodio N Noncoding RNA. 2023; 9(1).

PMID: 36827549 PMC: 9964195. DOI: 10.3390/ncrna9010016.

Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer.

Gong W, Zhu C, Liu Y, Muckenhuber A, Bronger H, Scorilas A Am J Transl Res. 2021; 13(3):1594-1606.

PMID: 33841682 PMC: 8014413.

MicroRNA-4500 Inhibits Migration, Invasion, and Angiogenesis of Breast Cancer Cells via RRM2-Dependent MAPK Signaling Pathway.

Li S, Mai H, Zhu Y, Li G, Sun J, Li G Mol Ther Nucleic Acids. 2020; 21:278-289.

PMID: 32615527 PMC: 7330432. DOI: 10.1016/j.omtn.2020.04.018.

Development of Prediction Model Including MicroRNA Expression for Sentinel Lymph Node Metastasis in ER-Positive and HER2-Negative Breast Cancer.

Okuno J, Miyake T, Sota Y, Tanei T, Kagara N, Naoi Y Ann Surg Oncol. 2020; 28(1):310-319.

PMID: 32583195 DOI: 10.1245/s10434-020-08735-9.

References

Du W, Fang L, Li M, Yang X, Liang Y, Peng C . MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J Cell Sci. 2013; 126(Pt 6):1440-53. DOI: 10.1242/jcs.118299. View

Singletary S, Allred C, Ashley P, Bassett L, Berry D, Bland K . Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003; 83(4):803-19. DOI: 10.1016/S0039-6109(03)00034-3. View

Shatseva T, Lee D, Deng Z, Yang B . MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J Cell Sci. 2011; 124(Pt 16):2826-36. DOI: 10.1242/jcs.077529. View

Yan L, Huang X, Shao Q, Huang M, Deng L, Wu Q . MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008; 14(11):2348-60. PMC: 2578865. DOI: 10.1261/rna.1034808. View

Macabeo-Ong M, Ginzinger D, Dekker N, McMillan A, Regezi J, Wong D . Effect of duration of fixation on quantitative reverse transcription polymerase chain reaction analyses. Mod Pathol. 2002; 15(9):979-87. DOI: 10.1097/01.MP.0000026054.62220.FC. View

Laios A, OToole S, Flavin R, Martin C, Kelly L, Ring M . Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008; 7:35. PMC: 2383925. DOI: 10.1186/1476-4598-7-35. View

Sun Y, Wang M, Lin G, Sun S, Li X, Qi J . Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One. 2012; 7(10):e47003. PMC: 3468565. DOI: 10.1371/journal.pone.0047003. View

Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y . miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 2013; 15(3):284-94. PMC: 3672398. DOI: 10.1038/ncb2690. View

Deng Z, Du W, Fang L, Shan S, Qian J, Lin J . The intermediate filament vimentin mediates microRNA miR-378 function in cellular self-renewal by regulating the expression of the Sox2 transcription factor. J Biol Chem. 2012; 288(1):319-31. PMC: 3537029. DOI: 10.1074/jbc.M112.418830. View

10.

Xiang Q, Tang H, Yu J, Yin J, Yang X, Lei X . MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. Pharmazie. 2013; 68(4):274-81. View

11.

Chan J, Krichevsky A, Kosik K . MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005; 65(14):6029-33. DOI: 10.1158/0008-5472.CAN-05-0137. View

12.

Mello C, Czech M . Micromanaging insulin secretion. Nat Med. 2004; 10(12):1297-8. DOI: 10.1038/nm1204-1297. View

13.

Goswami R, Waldron L, Machado J, Cervigne N, Xu W, Reis P . Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples. BMC Biotechnol. 2010; 10:47. PMC: 2902407. DOI: 10.1186/1472-6750-10-47. View

14.

Negrini M, Ferracin M, Sabbioni S, Croce C . MicroRNAs in human cancer: from research to therapy. J Cell Sci. 2007; 120(Pt 11):1833-40. DOI: 10.1242/jcs.03450. View

15.

Baumjohann D, Kageyama R, Clingan J, Morar M, Patel S, de Kouchkovsky D . The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol. 2013; 14(8):840-8. PMC: 3720769. DOI: 10.1038/ni.2642. View

16.

Colangelo T, Fucci A, Votino C, Sabatino L, Pancione M, Laudanna C . MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia. 2013; 15(9):1086-99. PMC: 3769887. DOI: 10.1593/neo.13998. View

17.

Ye G, Fu G, Cui S, Zhao S, Bernaudo S, Bai Y . MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci. 2011; 124(Pt 3):359-68. DOI: 10.1242/jcs.072223. View

18.

Fu S, Chen L, Man Y . miRNA Biomarkers in Breast Cancer Detection and Management. J Cancer. 2011; 2:116-22. PMC: 3072617. DOI: 10.7150/jca.2.116. View

19.

Hebert C, Norris K, Scheper M, Nikitakis N, Sauk J . High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer. 2007; 6:5. PMC: 1783857. DOI: 10.1186/1476-4598-6-5. View

20.

Qian J, Lin J, Qian W, Ma J, Qian S, Li Y . Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia. Leuk Res. 2013; 37(7):765-8. DOI: 10.1016/j.leukres.2013.03.014. View